Role of SUMO Conjugation in Ischemia: Significance, Mechanisms and Pathways

SUMO 结合在缺血中的作用:意义、机制和途径

基本信息

  • 批准号:
    8421582
  • 负责人:
  • 金额:
    $ 34.34万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-15 至 2017-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Small ubiquitin-like modifier (SUMO) conjugation modulates all major cellular pathways, including those associated with gene expression and genome stability, protein quality control, proteasomal degradation of proteins and DNA damage repair. Transient cerebral ischemia massively activates SUMO conjugation, resulting in a dramatic rise in levels of SUMO2/3-conjugated proteins. Cell culture studies suggest that the post- ischemic activation of SUMO2/3 conjugation is a protective stress response. However, the role of SUMO conjugation in the fate of post-ischemic neurons in the intact brain and the mechanisms and pathways that link SUMO conjugation to restoration of function impaired by transient ischemia are not known. Without this knowledge it is highly unlikely that the SUMO conjugation pathway can be manipulated for therapeutic purposes. Our long-term goal is to understand how to manipulate the SUMO conjugation pathway for preventive and therapeutic purposes. The objective of this particular application is to elucidate the role of individual SUMO paralogues in the recovery of neurons from ischemic stress and to identify the mechanisms and pathways involved. The central hypothesis is that SUMO conjugation plays a key role in modulating path- ways that are critical for death/survival decisions in post-ischemic neurons. This hypothesis has been formulated on the basis of data produced in our laboratory. The rationale for the proposed studies is that after we have verified the protective role of SUMO conjugation in post-ischemic neurons in vivo and have identified the underlying mechanisms and pathways, we will have established an important platform for designing new strategies for preventive and therapeutic interventions in clinically relevant pathological states associated with a transient episode of insufficient blood supply. Based on strong preliminary data and the development of novel SUMO transgenic and knockout animals in our laboratory, the hypothesis will be tested by pursuing the following specific aims: 1) Characterize new SUMO transgenic and knockout mouse models; 2) Determine the effects of individual SUMO paralogues on post-ischemic neuronal cell damage and functional recovery; 3) Determine how SUMO conjugation is linked to the fate of post-ischemic neurons; 4) Determine how transient ischemia affects the crosstalk between ubiquitin and SUMO conjugation. The approach is innovative because it is the first study to use SUMO transgenic and knockout animals and to per- form proteomic analyses to determine the role of SUMO conjugation in cerebral ischemia. The proposed research is significant, because we expect to uncover the mechanisms that link SUMO conjugation to the viability and function of post-ischemic neurons. Ultimately, such knowledge is expected to translate into new strategies for therapeutic intervention in pathological states associated with an episode of insufficient blood supply and in other disorders associated with the SUMO conjugation pathway, including diabetes, heart failure, and degenerative diseases. PUBLIC HEALTH RELEVANCE: The proposed research is relevant to public health because elucidating the role of small ubiquitin-like modifier conjugation in the life/death decision of pos-ischemic neurons is expected to help identifying new targets for therapeutic intervention. Thus, the proposed research is relevant to the part of NIH's mission to foster fundamental creative discoveries, innovative research strategies, and their applications as a basis to advance significantly the Nation's capacity to protect and improve health.
描述(由申请人提供):小泛素样修饰物(SUMO)结合调节所有主要细胞途径,包括与基因表达和基因组稳定性、蛋白质质量控制、蛋白质的蛋白酶体降解和DNA损伤修复相关的途径。短暂性脑缺血大量激活SUMO结合,导致SUMO 2/3结合蛋白水平急剧上升。细胞培养研究表明,SUMO 2/3结合的缺血后激活是一种保护性应激反应。然而,SUMO缀合在完整脑中缺血后神经元的命运中的作用以及将SUMO缀合与短暂缺血受损的功能恢复联系起来的机制和途径尚不清楚。如果没有这些知识,就不太可能操纵SUMO缀合途径用于治疗目的。我们的长期目标是了解如何操纵SUMO结合途径用于预防和治疗目的。这个特殊的应用程序的目的是阐明个人的SUMO旁系同源物在恢复神经元从缺血性应激的作用,并确定所涉及的机制和途径。中心假设是SUMO缀合在调节对缺血后神经元的死亡/存活决定至关重要的通路中起关键作用。这一假设是根据我们实验室的数据提出的。提出的研究的基本原理是,在我们已经验证了SUMO缀合在体内缺血后神经元中的保护作用并确定了潜在的机制和途径之后,我们将建立一个重要的平台,用于设计新的策略,用于在与缺血相关的临床相关病理状态中进行预防和治疗干预。 短暂的血液供应不足基于我们实验室的大量初步数据和新型SUMO转基因和基因敲除动物的发展,我们将通过以下具体目标来验证这一假设:1)表征新的SUMO转基因和基因敲除小鼠模型; 2)确定单个SUMO旁系同源物对缺血后神经元细胞损伤和功能恢复的影响; 3)确定SUMO缀合如何与缺血后神经元的命运相关联; 4)确定短暂缺血如何影响泛素和SUMO缀合之间的串扰。该方法是创新的,因为它是第一个使用SUMO转基因和基因敲除动物并进行蛋白质组学分析以确定SUMO结合在脑缺血中的作用的研究。这项研究意义重大,因为我们希望揭示将SUMO结合与缺血后神经元的活力和功能联系起来的机制。最终,这些知识有望转化为新的策略,用于治疗与血液供应不足相关的病理状态以及与SUMO结合途径相关的其他疾病,包括糖尿病,心力衰竭和退行性疾病。 公共卫生关系:拟议的研究与公共卫生有关,因为阐明小泛素样修饰物缀合在缺血后神经元的生/死决定中的作用有望有助于确定治疗干预的新靶点。因此,拟议的研究是相关的NIH的使命的一部分,以促进基本的创造性发现,创新的研究策略,及其应用的基础上,大大提高国家的能力,以保护和改善健康。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

WULF PASCHEN其他文献

WULF PASCHEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('WULF PASCHEN', 18)}}的其他基金

Effect of Aging on Brain Ischemia/Stroke Outcome; Pathways, Mechanisms, and Rescue
衰老对脑缺血/中风结果的影响;
  • 批准号:
    9158636
  • 财政年份:
    2016
  • 资助金额:
    $ 34.34万
  • 项目类别:
Role of SUMO Conjugation in Ischemia: Significance, Mechanisms and Pathways
SUMO 结合在缺血中的作用:意义、机制和途径
  • 批准号:
    9049555
  • 财政年份:
    2012
  • 资助金额:
    $ 34.34万
  • 项目类别:
Restoration of Endoplasmic Reticulum Function in Experimental Stroke
实验性脑卒中内质网功能的恢复
  • 批准号:
    8439611
  • 财政年份:
    2012
  • 资助金额:
    $ 34.34万
  • 项目类别:
Role of SUMO Conjugation in Ischemia: Significance, Mechanisms and Pathways
SUMO 结合在缺血中的作用:意义、机制和途径
  • 批准号:
    8539860
  • 财政年份:
    2012
  • 资助金额:
    $ 34.34万
  • 项目类别:
Restoration of Endoplasmic Reticulum Function in Experimental Stroke
实验性脑卒中内质网功能的恢复
  • 批准号:
    8536412
  • 财政年份:
    2012
  • 资助金额:
    $ 34.34万
  • 项目类别:
SUMO Conjugation and Deep Hypothermia-Induced Organ Protection
SUMO 结合和深低温诱导的器官保护
  • 批准号:
    8217294
  • 财政年份:
    2010
  • 资助金额:
    $ 34.34万
  • 项目类别:
SUMO Conjugation and Deep Hypothermia-Induced Organ Protection
SUMO 结合和深低温诱导的器官保护
  • 批准号:
    8019079
  • 财政年份:
    2010
  • 资助金额:
    $ 34.34万
  • 项目类别:
SUMO Conjugation and Deep Hypothermia-Induced Organ Protection
SUMO 结合和深低温诱导的器官保护
  • 批准号:
    7779910
  • 财政年份:
    2010
  • 资助金额:
    $ 34.34万
  • 项目类别:
Conditional Gene Silencing in Ischemia/Stroke Research
缺血/中风研究中的条件基因沉默
  • 批准号:
    7676708
  • 财政年份:
    2008
  • 资助金额:
    $ 34.34万
  • 项目类别:
Shutdown of Translation and Ischemia/Stroke-Induced Cell Death
翻译的关闭和缺血/中风诱导的细胞死亡
  • 批准号:
    7470328
  • 财政年份:
    2008
  • 资助金额:
    $ 34.34万
  • 项目类别:

相似国自然基金

Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
  • 批准号:
    31171277
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
  • 批准号:
    31070748
  • 批准年份:
    2010
  • 资助金额:
    34.0 万元
  • 项目类别:
    面上项目

相似海外基金

Tissue tropism of PD-1 therapy in ulcerative colitis and rheumatoid arthritis
PD-1治疗溃疡性结肠炎和类风湿性关节炎的组织向性
  • 批准号:
    MR/Y009681/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.34万
  • 项目类别:
    Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
  • 批准号:
    MR/Y022947/1
  • 财政年份:
    2024
  • 资助金额:
    $ 34.34万
  • 项目类别:
    Research Grant
Preclinical development of an extracellular vesicle biotherapeutic for juvenile idiopathic arthritis
幼年特发性关节炎细胞外囊泡生物治疗药物的临床前开发
  • 批准号:
    10068495
  • 财政年份:
    2024
  • 资助金额:
    $ 34.34万
  • 项目类别:
    Collaborative R&D
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
  • 批准号:
    24K19237
  • 财政年份:
    2024
  • 资助金额:
    $ 34.34万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Exploring the inflammatory mediators degraded by MMP-2 in MMP-2-deficient mice with knee arthritis through a novel TMT-TAILS quantitative proteomics
通过新型 TMT-TAILS 定量蛋白质组学探索 MMP-2 缺陷型膝关节炎小鼠中 MMP-2 降解的炎症介质
  • 批准号:
    24K19850
  • 财政年份:
    2024
  • 资助金额:
    $ 34.34万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of an adaptive platform trial to prevent Rheumatoid Arthritis in partnership with First Nations People.
与原住民合作开发预防类风湿关节炎的适应性平台试验。
  • 批准号:
    491810
  • 财政年份:
    2023
  • 资助金额:
    $ 34.34万
  • 项目类别:
    Operating Grants
The role of diet, as mediated by the gut microbiome, on childhood arthritis disease activity: a feasibility intervention study.
肠道微生物组介导的饮食对儿童关节炎疾病活动的作用:一项可行性干预研究。
  • 批准号:
    489316
  • 财政年份:
    2023
  • 资助金额:
    $ 34.34万
  • 项目类别:
    Operating Grants
DEMORA: DEep spatial characterization of synovial MacrOphages in Rheumatoid Arthritis
DEMORA:类风湿性关节炎滑膜巨噬细胞的深度空间特征
  • 批准号:
    EP/Y027760/1
  • 财政年份:
    2023
  • 资助金额:
    $ 34.34万
  • 项目类别:
    Fellowship
Investigation of hypoxia-inducible factor-1 (HIF-1) as a novel therapeutic target for juvenile idiopathic arthritis.
研究缺氧诱导因子-1 (HIF-1) 作为幼年特发性关节炎的新治疗靶点。
  • 批准号:
    23K14987
  • 财政年份:
    2023
  • 资助金额:
    $ 34.34万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Novel first-in-class Therapeutics for Rheumatoid Arthritis
类风湿关节炎的一流新疗法
  • 批准号:
    10696749
  • 财政年份:
    2023
  • 资助金额:
    $ 34.34万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了